0000000000320744
AUTHOR
Vitale G.
showing 9 related works from this author
Predictive factors of response to mTOR inhibitors in neuroendocrine tumours
2016
Medical treatment of neuroendocrine tumours (NETs) has drawn a lot of attention due to the recent demonstration of efficacy of several drugs on progression-free survival, including somatostatin analogs, small tyrosine kinase inhibitors and mTOR inhibitors (or rapalogs). The latter are approved as therapeutic agents in advanced pancreatic NETs and have been demonstrated to be effective in different types of NETs, with variable efficacy due to the development of resistance to treatment. Early detection of patients that may benefit from rapalogs treatment is of paramount importance in order to select the better treatment and avoid ineffective and expensive treatments. Predictive markers for th…
Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
2019
Purpose: Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine carcinoma arising from the skin. We aimed to review and deal with some of the most relevant controversial topics on the correct use of immunotherapy for the treatment of MCC. Methods: The primary search was carried out via PubMed, EMBASE, and the Cochrane Library (until 31st May, 2018), while other articles and guidelines were retrieved from related papers or those referenced in these papers. Additionally, we performed an extensive search on ClinicalTrials.gov to gather information on the ongoing clinical trials related to this specific topic. Results: We performed an up-to-date critical review taking into account the…
PROGETTAZIONE OTTIMIZZATA DI FILTRI EMI AD ELEVATA POWER DENSITY PER CONVERTITORI ELETTRONICI DI POTENZA
2016
In molti dei campi di impiego dei convertitori elettronici di potenza (aeronautico, aerospaziale, automotive, etc.) è richiesta la realizzazione di sistemi di conversione che, in relazione a stringenti vincoli di progetto, presentino, a parità di potenza, dimensioni sempre più compatte e pesi ridotti. In tale ottica, l’ottimizzazione della densità di potenza (power density) del convertitore diventa un obiettivo essenziale
A six legs buck-boost interleaved converter for KERS application
2020
This paper addresses the design of a bi-directional DC/DC power converter to interface a supercapacitor bank and a motor-generator unit. The design is based on an interleaved six legs topology in which the current is shared among six inductors to minimize their weight and cost, allowing, besides, a low switching frequency to lessen switching losses. The converter is conceived to be employed in an electric Kinetic Energy Recovery System for Internal Combustion Engine Vehicles. The system makes use of a supercapacitor as a storage system, and a motorgenerator unit connected to the drive shaft for vehicle acceleration and braking. The system uses available commercial devices, thus obtaining a …
EMI Worsening in a SMPS with Non-linear Inductor
2022
This paper is focused on the input current in a Switched Mode Power Supply (SMPS) in which the power inductor is exploited up to the saturation showing a non-linear behaviour. The input current exhibits a distortion due to the non-linearity. The electromagnetic interference (EMI) caused by the ripple at switching frequency, superimposed to the DC value of the input current, requires a suitable design of the input differential mode (DM) filter. The input current is analyzed both in the time and frequency domain for different operating conditions, and it is compared to a SMPS equipped with a traditional linear inductor.
Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks
2021
Pheochromocytoma and paraganglioma are neuroendocrine neoplasms, originating in the adrenal medulla and in parasympathetic and sympathetic autonomic nervous system ganglia, respectively. They usually present as localized tumours curable with surgery. However, these tumours may exhibit heterogeneous clinical course, ranging from no/minimal progression to aggressive (progressive/metastatic) behavior. For this setting of patients, current therapies are unsatisfactory. Immune checkpoint inhibitors have shown outstanding results for several types of solid cancers. We therefore aimed to summarize and discuss available data on efficacy and safety of current FDA-approved immune checkpoint inhibitor…